Elispot Assay Of Interferon-Gamma Secretion For Evaluating Human Cytomegalovirus Reactivation Risk In Allo-Hsct Recipients

Human cytomegalovirus (HCMV) is a common cause of significant morbidity and mortality in transplant recipients after allogeneic hematopoietic stem cell transplantation (allo-HSCT). We evaluated interferon-gamma (IFN-gamma) secretion by HCMV NLV-specific CD8(+) T cells in HCMV-reactivated allo-HSCT recipients using an enzyme-linked immunospot (ELISPOT) assay at 3 months post-transplantation. Blood samples from 47 recipients were tested for HCMV DNAemia, HCMV pp65 antigenemia, and anti-HCMV immunoglobulins (IgG/IgM) over 3 months post-transplantation. Of the 47 transplant recipients, 26 were HLA-A*02 positive and 21 were HLA-A*02 negative. The results were essentially consistent between the 47 transplant recipients and the HLA-A*02-positive recipients. HCMV DNAemia was not linearly correlated with IFN-gamma spot-forming cells (SFCs) counts; IFN-gamma SFCs counts did not differ significantly between the HCMV DNAemia-positive and -negative groups, whereas the HCMV-DNA virus loads were inversely correlated with the IFN-gamma SFCs counts. HCMV pp65 antigenemia was not linearly correlated with IFN-gamma SFCs counts; IFN-gamma SFCs counts in the HCMV pp65 antigenemia-positive and -negative groups were similar. More IFN-gamma SFCs counts were detected in transplant recipients with high anti-HCMV-IgG antibody titers than in those with low anti-HCMV-IgG titers pre-transplantation in the 47 recipients. Anti-HCMV-IgG antibody titers were positively linearly correlated with IFN-gamma SFCs counts in HLA-A*02-positive recipients. The HCMV infection indicators used to monitor HCMV reactivation had different values in transplant recipients. The use of the IFN-gamma SFCs counts measured by ELISPOT to evaluate the risk of HCMV reactivation needs further study.